Cumberland Pharmaceuticals Inc. (Cumberland), is specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. Cumberland is focused on acquiring rights to, developing and commercializing prescription products for the hospital care and gastroenterology markets. Its product portfolio includes Acetadote (acetylcysteine), Caldolor (ibuprofen), Kristalose (lactulose) and Hepatoren (ifetroban). As of December 31, 2011, Hepatoren was in Phase II clinical development. The Company markets and sells its products through its hospital and gastroenterology sales forces in the United States. Its pre-clinical product candidates are being developed through its 85% owned subsidiary Cumberland Emerging Technologies, Inc. In March 2014, the Company acquired Vaprisol from Astellas Pharma US Inc.